NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 129 filers reported holding NURIX THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.78 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,944,174 | -27.5% | 1,774,068 | -7.9% | 0.00% | 0.0% |
| Q2 2023 | $19,238,003 | -3.1% | 1,925,726 | -13.8% | 0.00% | 0.0% |
| Q1 2023 | $19,849,269 | -64.0% | 2,235,278 | -55.4% | 0.00% | -50.0% |
| Q4 2022 | $55,075,394 | +82.8% | 5,015,974 | +116.9% | 0.00% | 0.0% |
| Q3 2022 | $30,128,000 | +12.3% | 2,312,224 | +9.2% | 0.00% | 0.0% |
| Q2 2022 | $26,819,000 | -16.9% | 2,116,771 | -8.1% | 0.00% | 0.0% |
| Q1 2022 | $32,259,000 | -28.5% | 2,302,544 | +47.8% | 0.00% | 0.0% |
| Q4 2021 | $45,096,000 | -7.8% | 1,557,712 | -4.6% | 0.00% | -33.3% |
| Q3 2021 | $48,929,000 | -0.8% | 1,633,131 | -12.2% | 0.00% | 0.0% |
| Q2 2021 | $49,332,000 | +15.2% | 1,859,468 | +35.0% | 0.00% | +50.0% |
| Q1 2021 | $42,838,000 | +188.7% | 1,377,862 | +205.4% | 0.00% | +100.0% |
| Q4 2020 | $14,837,000 | +222.8% | 451,232 | +242.7% | 0.00% | – |
| Q3 2020 | $4,597,000 | – | 131,673 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ponoi II Management, LLC | 561,574 | $16,825,000 | 24.93% |
| Ponoi Management, LLC | 561,573 | $16,825,000 | 14.94% |
| TRV GP III, LLC | 2,422,549 | $72,580,000 | 13.78% |
| Foresite Capital Management IV, LLC | 1,205,798 | $36,126,000 | 5.32% |
| Foresite Capital Management V, LLC | 451,522 | $13,528,000 | 4.20% |
| WestHill Financial Advisors, Inc. | 283,333 | $8,489,000 | 2.62% |
| DAFNA Capital Management LLC | 306,320 | $9,177,000 | 2.44% |
| Bain Capital Life Sciences Investors, LLC | 1,284,314 | $38,478,000 | 2.39% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 571,212 | $17,113,000 | 2.02% |
| Redmile Group, LLC | 3,093,077 | $92,669,000 | 1.62% |